The KRT7 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the KRT7 gene in a human ovarian cancer model. This product consists of a heterogeneous pool of A2780 cells subjected to CRISPR/Cas9-mediated disruption of the keratin 7 locus, resulting in a mixed population with targeted gene ablation. The polyclonal format provides a robust and reproducible model for examining KRT7-dependent phenotypes without the clonal variability associated with single-cell-derived isolates. By employing a polyclonal knockout strategy, researchers can investigate the collective impact of KRT7 loss on epithelial cell biology in a physiologically relevant cancer cell background, making it well-suited for high-throughput screening and population-level studies of intermediate filament dynamics.
The host cell line, A2780, is a well-characterized human ovarian endometrioid adenocarcinoma epithelial cell line originally derived from an untreated patient with ovarian carcinoma. A2780 cells are widely utilized as a model system for ovarian cancer research, particularly in studies of tumor progression, metastasis, and drug resistance. Their epithelial origin and malignant properties render them an ideal platform for dissecting the contributions of cytoskeletal proteins to cancer cell behavior. The A2780 line retains key features of ovarian carcinoma, including responsiveness to chemotherapeutic agents, which facilitates the exploration of how keratin networks influence therapeutic sensitivity and resistance mechanisms. This genetic background provides a clinically relevant context for functional genomics approaches targeting structural proteins.
Keratin 7, encoded by KRT7, is a type II intermediate filament protein predominantly expressed in simple epithelia and their malignant counterparts. It pairs obligatorily with the type I keratin KRT19 to form heterodimers that assemble into 10-nm filaments, contributing to the mechanical integrity and viscoelastic properties of epithelial cells. KRT7-containing filaments are integral components of the cytoskeletal network, interacting with desmosomal plaque proteins such as Desmoplakin, Plakoglobin, and Desmocollin, thereby linking the intermediate filament system to cell-cell adhesion complexes. KRT7 expression is regulated by upstream signaling pathways, including WNT/??-catenin-mediated transcription through TCF/LEF factors and NF-??B activation, while also being responsive to mechanical stress. Downstream, KRT7 influences cytoskeletal organization, the stability of cell adhesion assemblies, and the expression of epithelial-mesenchymal transition (EMT) markers, positioning it at the intersection of mechanical sensing and signaling circuits that govern epithelial plasticity.
In the A2780 ovarian carcinoma context, disruption of KRT7 by CRISPR/Cas9 disrupts the intermediate filament network and compromises the structural resilience of these cancer cells. Loss of KRT7 likely impairs the keratin-desmosome interface, potentially weakening cell-cell adhesion and altering collective cell migration patterns. This knockout model enables dissection of KRT7??s role in maintaining epithelial architecture under the mechanical stresses encountered during tumor growth and invasion. Furthermore, because KRT7 is a marker of ovarian endometrioid adenocarcinoma, its deletion provides a unique tool to study the molecular consequences of keratin loss in a disease-relevant background, including potential crosstalk with ??-catenin/E-cadherin adhesion signaling and impacts on downstream EMT programs. The model thereby offers a platform to explore how intermediate filament disruption sensitizes ovarian cancer cells to cytoskeletal-targeting agents or microenvironmental challenges.
Research applications for this KRT7 knockout polyclonal cell pool are diverse and technically rigorous. Investigators can employ the cells in wound healing and Transwell migration assays to assess the contribution of keratins to cell motility and invasive capacity. Immunofluorescence staining of intermediate filament proteins, including KRT7 and its partner KRT19, combined with Desmoplakin and E-cadherin co-labeling, allows visualization of adhesion complex integrity. Western blotting and transcriptomic analyses (e.g., RNA-seq) can be used to profile global changes in EMT markers, cytoskeletal regulators, and stress-response pathways. Researchers may also perform drug sensitivity and resistance profiling to evaluate how KRT7 ablation modulates therapeutic responses in ovarian cancer. By integrating these approaches, this knockout model serves as a valuable resource for studies of cancer cell mechanics, metastatic progression, and the signaling networks underpinning epithelial cancer biology. For further information, please contact Ascent Research.
